Regeneron extends U.S. supply deal for Ebola drug Inmazeb worth about $270 million
Regeneron extended its contract with the U.S. government to supply its Ebola treatment Inmazeb through 2031. The deal is worth about $270 million, Dow Jones Newswires reports.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Regeneron Pharmaceuticals has extended its supply agreement with the U.S. government, agreeing to provide additional doses of its Ebola treatment through 2031. The deal is worth about $270 million. The counterparty is BARDA, a unit of the Administration for Strategic Preparedness and Response. Dow Jones Newswires reported that the company announced the agreement on Monday. Inmazeb is a three-antibody cocktail that has been given to hundreds of patients since 2019 for infection caused by Orthoebolavirus zairense.
why it matters
For markets this is mainly a company-level story, with limited impact on the broader market. The extended government order adds predictable revenue for Regeneron as Ebola cases linked to the Bundibugyo strain rise in the Democratic Republic of the Congo and appear in Nigeria and Kenya.
tags
instruments
sources
- Regeneron Secures $270M U.S. Contract Extension for Ebola Treatment Inmazeb — Dow Jones Newswires, 26 October 2026 at 11:35 UTC
- Regeneron Secures $270 Million U.S. Contract Extension for Ebola Treatment Inmazeb — Dow Jones Newswires, 26 October 2026 at 11:50 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗